CONCENTRA GROUP HOLDINGS PAREN SEC Filings

Concentra Group Holdings Parent, Inc. (CON) reported an insider equity grant. On 11/04/2025, an officer received 60,000 shares of common stock at a price of $0 under a restricted stock award. Following the grant, the officer beneficially owns 120,000 shares, held directly.

The award is described as restricted stock that will vest in equal annual installments over four years. The reporting person is identified as Executive Vice President, Chief Growth & Customer Officer. The transaction was coded as an acquisition of securities.

Concentra Group Holdings Parent (CON) reported a director’s equity award on Form 4. On 11/04/2025, the reporting person acquired 7,748 shares of Common Stock at $0, disclosed as a grant of restricted stock. Following the transaction, the director beneficially owns 20,740 shares, held directly.

The restricted stock grant will vest in full on November 4, 2026, subject to stated exceptions. This filing reflects an equity compensation event rather than an open‑market purchase.

Concentra Group Holdings Parent, Inc. disclosed an insider equity grant. On 11/04/2025, an officer received 60,000 shares of common stock as restricted stock at $0 under a grant that vests in equal annual installments over four years. Following the award, the reporting person beneficially owns 120,000 shares, held directly. The filer is the company’s Executive Vice President, Chief Digital & Data Officer. Transaction code: A (grant).

Concentra Group Holdings Parent, Inc. (CON) reported an insider equity grant. A company officer filed a Form 4 showing acquisition of 60,000 shares of common stock as a restricted stock grant at $0 on 11/04/2025. Following this grant, the officer directly beneficially owns 120,000 shares. The award will vest in equal annual installments over four years.

Concentra Group Holdings Parent, Inc. (CON) disclosed an insider equity grant. A director received 7,748 shares of common stock on 11/04/2025 at $0 as a restricted stock award that will vest in full on 11/04/2026.

Following this grant, the reporting person beneficially owns 20,740 shares, held directly.

Concentra Group Holdings Parent, Inc. (CON) reported a director equity award on a Form 4. On 11/04/2025, the director acquired 15,496 shares of common stock via two restricted stock grants at a stated price of $0.

One grant covered 7,748 shares that vest in equal annual installments over five years. A second grant covered 7,748 shares that, subject to certain exceptions, vest in full on November 4, 2026, the first anniversary of the grant date. Following these grants, the Form 4 shows 15,496 shares beneficially owned directly.

Concentra Group Holdings Parent, Inc. reported higher Q3 results. Revenue reached $572.8 million versus $489.6 million a year ago, and net income attributable to the company was $48.3 million versus $44.3 million. Basic and diluted EPS were $0.38 compared with $0.37.

Year to date, revenue was $1.624 billion versus $1.435 billion, while net income attributable to the company was $131.7 million versus $145.0 million. Operating cash flow was $160.7 million; cash ended at $49.9 million after investing $394.7 million, driven mainly by acquisitions.

The company completed the Nova Medical Centers acquisition for $265.0 million and the Pivot Onsite Innovations acquisition for $54.4 million. Q3 revenue included Nova $31.3 million and Pivot $16.6 million. Debt consisted of $650.0 million 6.875% senior notes and credit facilities including a Term Loan with $945.3 million principal outstanding; the revolver provided $393.0 million availability. The reported leverage ratio was 3.6x. The network operated 628 occupational health centers and 413 onsite clinics as of September 30, 2025.

Concentra Group Holdings Parent, Inc. announced two capital return actions alongside furnishing its third‑quarter results materials. The Board declared a cash dividend of $0.0625 per share, payable on or about December 9, 2025 to stockholders of record as of the close of business on December 2, 2025.

The Board also authorized a share repurchase program of up to $100 million of common stock, expiring on December 31, 2027. Repurchases may occur in the open market or through privately negotiated transactions, and the program will be funded with cash on hand. The company furnished a press release and financial presentation for the quarter ended September 30, 2025 as exhibits.

Concentra Group Holdings Parent, Inc. — Form 10-Q (Quarter ended June 30, 2025)

Q2 2025 revenue rose to $550.8 million versus $477.9 million in Q2 2024 (+~15%). Six-month revenue was $1,051.5 million versus $945.5 million. Despite revenue growth, net income attributable to the company declined to $44.6 million for the quarter (Q2 2024: $51.7 million); EPS fell to $0.35 (Q2 2024: $0.50). Cash declined to $73.9 million from $183.3 million at year-end 2024.

Material corporate actions: acquisition of Nova Medical Centers (closed March 1, 2025) for a preliminary purchase price of $265.0 million and Pivot Onsite Innovations (closed June 1, 2025) for $54.4 million. Goodwill increased materially (preliminary goodwill of $206.96M and $34.43M). Company amended credit facilities (revolver increased to $450M; incremental term loan $102.1M); net leverage was 3.8x (covenant 6.5x). AOCI shows $3.9 million loss from hedges. Significant contingencies include a multi-million patient data-breach class action matter and DOJ inquiry regarding physical therapy billing; outcomes are uncertain. Board declared a $0.0625/share dividend payable Aug 28, 2025.